Vemurafenib: the first drug approved for BRAF-mutant cancer
Plex Pharmaceuticals (United States) · Toxikon (United States) · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
821
total citations
- FWCI
- 25.93
- Percentile
- 100%
- References
- 139
Citations per year
Authors
7- GBGideon BollagCorresponding
Plex Pharmaceuticals (United States)
- JTJames Tsai
Toxikon (United States), Universidad Estatal de Bolívar
- JZJiazhong Zhang
Toxikon (United States), Universidad Estatal de Bolívar
- CZChao Zhang
Toxikon (United States), Universidad Estatal de Bolívar
- PNPrabha N. Ibrahim
Universidad Estatal de Bolívar, Toxikon (United States)
Topics & keywords
Topics
Keywords
- Vemurafenib
- Druggability
- Medicine
- PTEN
- Drug development
- Metastatic melanoma
- Melanoma
- Cancer research
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.